These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod. Masera S; Chiavazza C; Mattioda A; Superti G; Beggiato E; Crosasso P; Broganelli P; Pinessi L; Cavalla P Mult Scler; 2014 Oct; 20(12):1666-7. PubMed ID: 24603883 [No Abstract] [Full Text] [Related]
26. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod]. Komoly S Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178 [No Abstract] [Full Text] [Related]
27. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Leypoldt F; Münchau A; Moeller F; Bester M; Gerloff C; Heesen C Neurology; 2009 Mar; 72(11):1022-4. PubMed ID: 19289744 [No Abstract] [Full Text] [Related]
28. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Tanaka M; Park K; Tanaka K Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501 [No Abstract] [Full Text] [Related]
29. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856 [No Abstract] [Full Text] [Related]
30. Fingolimod for multiple sclerosis. Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953 [TBL] [Abstract][Full Text] [Related]
31. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. Massberg S; von Andrian UH N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715 [No Abstract] [Full Text] [Related]
32. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Saab G; Almony A; Blinder KJ; Schuessler R; Brennan DC Arch Ophthalmol; 2008 Jan; 126(1):140-1. PubMed ID: 18195237 [No Abstract] [Full Text] [Related]
33. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Huggins A; Sergott RC Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305 [No Abstract] [Full Text] [Related]
34. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Min JH; Kim BJ; Lee KH Mult Scler; 2012 Jan; 18(1):113-5. PubMed ID: 22146605 [TBL] [Abstract][Full Text] [Related]
35. Management of fingolimod-associated macular edema. Chui J; Herkes GK; Chang A JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612 [No Abstract] [Full Text] [Related]
36. The pill times 2: what every woman with multiple sclerosis should know. Langer-Gould AM Neurology; 2014 Feb; 82(8):654-5. PubMed ID: 24463629 [No Abstract] [Full Text] [Related]
37. Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya. Clin Infect Dis; 2013 Oct; 57(8):ii. PubMed ID: 24195115 [No Abstract] [Full Text] [Related]